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ABSTRACT 
Sepsis is a condition characterized by a severe stage of blood-infection often leading to 
tissue damage, organ failure and finally death. Fast diagnosis and identification of the 
sepsis stage (sepsis, severe sepsis or septic shock) is critical for the patient´s evolution 
and could help in defining the most adequate treatment in order to reduce its mortality. 
The combined detection of several biomarkers in a timely, specific and simultaneous 
way could ensure a more accurate diagnosis. We have designed a new optical point-
of-care (POC) device based on a phase-sensitive interferometric biosensor with a 
label-free microarray configuration for potential high-throughput evaluation of specific 
sepsis biomarkers. The sensor chip, which relies on the use of metallic nanostructures, 
provides versatility in terms of biofunctionalization, allowing the efficient immobilization 
of different kind of receptors such as antibodies or oligonucleotides. We have focused 
on two structurally different types of biomarkers: proteins, including C-reactive protein 
(CRP) and Interleukin 6 (IL6) and miRNAs, using miRNA-16 as example. Limits of 
Detection (LoD) of 18 µg mL-1, 88 µg mL-1 and 1 µM (6 µg mL-1) have been respectively 
obtained for CRP, IL6 and miRNA-16 in individual assays, with high accuracy and 
reproducibility. The multiplexing capabilities have also been assessed with the 
simultaneous analysis of both protein biomarkers.  
Keywords: Point-of-care; label-free multiplexed biosensing; nanoplasmonics; sepsis; 
protein and miRNA biomarkers; microarray 
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Introduction 
Sepsis is a condition expressed as a critical whole-body inflammatory response due to 
an infection. The first stage of sepsis involves a systemic inflammatory response 
(SIRS), followed by a severe sepsis which is characterized by organ dysfunction (liver, 
kidney, lung and heart). Further deterioration results in a sepsis shock that could cause 
hypotension and, ultimately, death [1]. Currently, sepsis is the main cause of death in 
Intensive Care Units (ICU) and its incidence is increasing worldwide with a mortality 
rate between 40 to 50% in developed countries [1-4]. The mortality rate increases with 
delayed diagnosis or with inappropriate antibiotic therapy, which implies, besides the 
human losses, in a high economic cost for the healthcare systems [4]. A well-timed and 
precise diagnosis of sepsis is really essential for the on-time selection of the most 
appropriate therapy.  
Diagnosis of sepsis is not straightforward. There has been an extensive clinical 
research focused on identifying a reliable panel of biomarkers associated to sepsis. 
Currently, there are more than 170 different biomarkers that could be useful for either 
its diagnosis or prognosis [4]. Some of them are already used at clinical level for 
diagnosis and treatment monitoring. Different pro-inflammatory cytokines (TNF, IL-1β 
and IL6) as well as C-reactive protein (CRP) and procalcitonin (PCT) have been 
proposed, among others. CRP is an acute phase protein, well established as a 
biomarker for infection and inflammation. High levels of CRP (40 to 200 µg mL-1) and 
PCT (above 0.5 ng mL-1) are known to be related with sepsis infection [5, 6]. However, 
both biomarkers are also affected by other non-inflammatory processes, such as burns 
or traumas. Interleukin-6 (IL6), together with TNF-α and IL-1β, mediates the initial 
response of the innate immunity to injury or infection, enhancing the liver production of 
acute phase reactants, including CRP [1, 5]. Additionally, circulating microRNAs 
(miRNAs) are acquiring importance as biomarkers for the non-invasive detection of 
diseases [7]. The evaluation of miRNAs differential expression levels in body fluids 
Page 4 of 26 
 
such as blood, saliva or urine can be a useful tool for diagnosis and prognosis. Some 
of them have been identified for playing a relevant role in the progression, diagnosis 
and staging of sepsis (i.e. miRNA15a, miRNA-146a, miRNA-16 or miRNA-223, among 
others) [8 - 10].  
Protein biomarkers like CRP and IL6 are individually analyzed following conventional 
techniques such as immunoassays or flow cytometry, which are precise and reliable, 
but they are also time consuming and require specialized personnel [11]. For the 
detection of circulating miRNAs, the most common techniques are real-time reverse-
transcription polymerase chain reaction (qRT-PCR), northern blot and fluorescent 
microarray technology. Due to the small size of the miRNAs and their low concentration 
in biological fluids (pM - fM) these techniques need a large amount of sample, and 
sometimes lack sensitivity or robustness and are time-consuming [8]. 
Combining the detection of several of the most relevant biomarkers would increase the 
overall sensitivity and specificity of sepsis detection. Adding also the identification and 
quantification of the etiological infectious agent would ensure a more accurate 
diagnosis, a timely start of the appropriate antibiotic treatment and the improvement of 
the outcome of the sepsis process. Therefore, having a technology capable of 
detecting all these targets in a multiplexed analysis in a prompt, specific and 
simultaneous way, ideally at the patient’s bedside or the ICU, might enable proper 
stratification of SIRS and sepsis patients.  
Optical biosensors are ideal candidates for this purpose. Due to their integration 
capabilities they are excellent analytical tools to move the analysis from centralized 
laboratories to the point-of-care. Their design often offers fast turnaround times, easy-
to-handle features and in some cases, simultaneous detection capabilities [12]. Several 
optical devices using microarray formats to perform multiplexed assays have been 
previously proposed. Some of them are based on conventional labelled strategies (i.e. 
fluorescence or chemiluminescence) but others follow label-free approaches as the 
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reflectometric interference spectroscopy, surface plasmon resonance imaging or the 
arrayed imaging reflectometry (AIR) [13-15]. Kemmler et al. [15] proposed a POC 
device for sepsis diagnosis based on a microarray using Total Internal Reflection 
Fluorescence (TIRF). The POC was employed to evaluate several sepsis biomarkers 
but required fluorescent labels and involved several fluid handling steps such as 
dilution, mixing, separation, pre-incubation and incubation to carry on sandwich and 
inhibition assays. Internal calibration in the biochip was also needed to prevent 
inaccuracy. Also, Mace et al. [16] used their developed AIR technology to detect 
various cytokine proteins involved in the body inflammatory response. Specific 
antibody-based macroarrays were manually generated. The design of the device 
allowed visualization and tracking of up to 8 differentiated spots, which limited its 
multiplexing potential and produced a high variability among measurements.  
Recently, we presented a novel optical phase-sensitive interferometric biosensor based 
on microarray configuration as a new platform for high-throughput evaluation with 
potential of detecting specific biomarkers in blood plasma [17, 18]. This POC has been 
developed within the framework of a Horizon 2020 European project (RAIS, www.rais-
project.eu). The device has a small compact size (20 x 14 x 23 cm), is portable and 
user-friendly, giving results in around 1 minute. It requires 1 cm2 sensor chips and 
offers a large field of view (20 mm2). This feature facilitates the generation of dense 
arrays, which could allocate thousands of spots to be visualized simultaneously. We 
here demonstrate for the first time the feasibility of this POC device for the detection of 
protein and miRNA sepsis biomarkers. We have selected CRP and IL6 as protein 
targets, and miRNA-16 as miRNA model, being one of the several miRNAs with 
suspected diagnostic value to sepsis. We have developed and optimized all the 
biofunctionalization protocols and individual detection assays for each of those 
biomarkers. Moreover, we also show the multiplexed potential for the simultaneous 
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detection of CRP and IL6, demonstrating the capabilities of our POC device for fast 
and label-free diagnosis of several biomarkers. 
Materials and Methods 
Chemical and biological reagents  
Monoclonal antibody against CRP named ab183 (anti-CRP) was produced at and 
provided by DIESSE Diagnostica (Siena, Italy). Monoclonal antibody against IL6 (anti-
IL6) was purchased to Invitrogen (USA). CRP was obtained from BBI solutions 
(Cremlin, UK) and IL6 from Fitzgerald (Acton, USA). 
All the buffer compounds, PBS 50 mM (50 mM phosphate buffer, 0.75 M NaCl, 2 mM 
ethylenediaminetetraacetic acid (EDTA), pH 7), PBS 10 mM (10 mM phosphate buffer, 
0.15 M NaCl, pH 7), 5x SSC (0.75 M NaCl, 0.075 M sodium citrate, 4 mM EDTA, pH 7) 
were purchased from Sigma-Aldrich (Steinhem, Germany). Diethyl pyrocarbonate 
(DEPC), Protein G from Streptococcus sp. and bovine serum albumin (BSA) were 
purchased from Sigma-Aldrich (Steinhem, Germany). Oligo Analyzer software and 
RNA fold webserver was employed for secondary structure and self-annealing 
prediction of the probes and targets. DNA capture probes incorporating thiol (SH-DNA) 
at the 5’-end were purchased from IBIAN Technologies (Zaragoza, Spain) (see Table 
1). Antibody against DNA/RNA duplex (Anti-DNA/RNA) was purchased from Kerafast 
(Boston, USA). All the buffers and other solutions for miRNA detection were prepared 
using DEPC-H2O (MilliQ water incubated overnight with 0.1% DEPC and autoclaved for 
1h at 121 °C). All solid plastic and glass materials were autoclaved for 1h at 121 °C.  
Table 1. DNA capture probes and miRNAs nucleotide sequences for miRNA assay. 
miRNA Sequence DNA-SH capture probe  
miRNA-16 5’ UAGCAGCACGUAAAUAUUGGCG 3’ 5’ SH-T15-CGCCAATATTTACGT 3’ 
miRNA-21 5’ UAGCUUAUCAGACUGAUGUUGA 3’ 5’ SH-T15-TCAACATCAGTCTGA 3’ 
miRNA-15a  5’ SH-T15-CACAAACCATTATGT 3’ 
Optical instrument, readout and data processing 
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The POC device (dimensions: 20 x 14 x 23 cm) has three main parts: a light source 
consisting of an external fiber-coupled LED 660 nm (Thorlabs), optical components 
(detailed in [17]), and an electronic assembly that controls the components and 
communicates with the computer. The LED light source was chosen to spectrally 
overlap with the transmission peak of the gold nanohole array (Au-NHA) used as 
plasmonic sensor chip [18]. The binding events occurring on the surface of Au-NHA 
chips were monitored with a custom designed LabView software which records the 
phase changes and renders an OPD (optical path difference) map image.  
Spotting of Au-NHAs chips 
All the spotting experiments carried out for the generation of the microarrays have been 
performed by the ICTS “NANBIOSIS”, more specifically by the Unit of Biodeposition 
and Biodetection (U4) of CIBER in Bioengineering, Biomaterials & Nanomedicine 
(CIBER-BBN) at ICN2 facilities. A dip-pen nanolithography-based spotter (BioForce 
Nanosciences, Utah, USA) was used, which allows the deposition of minute amounts 
of solutions in a very precise and custom-designed manner. Several microarrays 
generated over the sensor chip with different sizes such as 8x8 or 10x10 spots (with an 
average diameter of around 55 µm and an array pitch of 250 µm) were routinely 
generated throughout all the experiments. 
Plasmonic Gold Nanohole Array chips  
Fabrication of the plasmonic sensor chips was done in a clean room using wafer-scale 
and high-throughput fabrication methods. Fused silica wafers were coated with Ti/Au 
(10/120 nm) and patterned with 200 nm diameter and 600 nm period nanohole arrays. 
The fabrication process is explained in detail in [18]. Before use, the Au-NHA chips 
(1x1 cm2) were cleaned by consecutive heating at 50º and sonicating (1 min) with 
solvents of increasing polarity (i.e. acetone, ethanol and MilliQ water). Then, they were 
dried with a N2 flow and placed in a UV/O3 chamber (Bioforce Nanoscience, Utah, 
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USA, included in the Unit of Biodeposition and Biodetection (U4), from the ICTS 
“NANBIOSIS”) for 30 min. The sensor chips were finally rinsed with ethanol and MilliQ 
water and dried with N2 flow.  
Biofunctionalization and protein measurements with Au- NHA chips   
The attachment of protein bioreceptors (antibodies) to the Au-NHA chips was done via 
Protein G capture to facilitate the orientation of the antibodies. Briefly, Protein G (500 
µg mL-1 in PBS 10 mM with 5% glycerol) was attached through non-covalent 
physisorption by direct spotting over clean Au-NHA sensor chips. The sensor chips 
were incubated for 2 h at room temperature (RT) and rinsed with PBS to remove 
unbound protein G. The sensor chips were incubated with a BSA solution (1% in PBS 
10 mM, 1 h at RT) to block remaining bare gold area and were rinsed again with PBS. 
The chips were then incubated with the antibody (250 µg mL-1 in PBS 10 mM, 2 h at 
RT) and finally rinsed with PBS and dried with N2. Calibration curves were obtained by 
evaluating different known concentrations of CRP or IL6 in triplicates (from 10 to 500 
µg mL-1 dissolved in PBS). Each step of the biofunctionalization was monitored by 
rinsing and drying the sensor chips and placing them in the POC device to obtain the 
OPD. The Limit of Detection (LoD) was calculated as three times the standard 
deviation of the signal corresponding to a blank sample. 
The multiplexed test was done by immobilization of both anti-CRP and anti-IL6 
antibodies. A sensor chip was divided in four sections. An 8x8 microarrays of Protein G 
was generated in each one of them. The four differentiated areas were separated by 
means of a hydrophobic pen that created a hydrophobic barrier that avoided sample 
mixing. Blocking with BSA (1%) for 30 min was also performed. Then two of the 
microarrays were incubated with anti-IL6 and two with anti-CRP antibodies (see Figure 
5). The sensor chip was then incubated with solutions containing either CRP, IL6 or a 
mixture of both (200 µg mL-1).  
Page 9 of 26 
 
Biofunctionalization and miRNA measurements with Au- NHA chips   
Biofunctionalization for miRNA detection was achieved via thiol-gold linkage by spotting 
a solution of SH-DNA capture probes (50 μM in PBS 50 mM with 10% glycerol) over 
clean Au-NHAs chips and incubating them overnight at RT. The sensor chips were 
rinsed with DEPC-H2O and incubated with BSA (0.1% in PBS 10 mM for 30 min) to 
block remaining gold area. The sensor chips were rinsed with DEPC-H2O water and 
dried with N2. Target miRNA (miRNA-16) at different concentrations (0.1 – 50 µM in 5x 
SSC buffer) was incubated with DNA spotted sensor chips for 1 h at RT. After rinsing, 
the sensor chips were incubated with anti-DNA/RNA (at a fixed concentration of 80 µg 
mL-1 diluted in 0.5x SSC) during 45 min at RT. Finally, the sensor chips were rinsed 
with DEPC-H2O water and dried with N2 flux. Each step of the biofunctionalization and 
detection was monitored by placing the rinsed and dried sensor chips in the POC 
device to obtain the OPD. Calibration curves were obtained by measuring different 
standards of known concentration of target miRNA-16 by triplicate. 
Calculation of the optical path difference (OPD)  
Each step of the assay was monitored by tracking the OPD signals of the spots. Upon 
binding of analyte, the total OPD of the spot increases. The plotted signal is the result 
of the difference in OPD value before (𝑂𝑃𝐷𝑡0 ) and after incubation (𝑂𝑃𝐷𝑡𝑡 ) with the 
target analyte (∆𝑂𝑃𝐷 = 𝑂𝑃𝐷𝑡𝑡 − 𝑂𝑃𝐷𝑡0 ). Calibration curves were fitted to a non-linear 
one site total binding equation (CRP and miRNA-16) or to a linear fitting (IL6). The 
ΔOPD and the standard deviation (SD) of each concentration were plotted versus the 
target concentration.  
 
Results and Discussion 
POC biosensor 
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The POC biosensor device has been previously described [17]. It is based on a lens-
free interferometric microscopy which evaluates changes in the topography of 
transparent surfaces, allowing direct observation of target-binding events. Briefly, the 
device is an optical microarray reader with large-field-of-view (20 mm2) (FOV), in which 
a polarized light beam is sheared into two beams (reference and signal, see Figure 1a) 
that pass through the sample. These two beams are then recombined and the final 
output light is recorded by a CMOS sensor. Changes in the phase of the light beams 
when passing through a transparent substrate create an interferometric pattern over 
the full FOV of the camera which is translated into an OPD map. Thus, local deviations 
in refractive index and thickness (such as biomarkers present in a sample) can be 
tracked by a camera and then processed by an algorithm to extract the OPD. The 
algorithm isolates each spot and its surroundings and calculates the difference 
between the maximum and the minimum phase-shift values found in that area, 
rendering the final OPD value for each spot. These light phase-shifts can be enhanced 
by the employment of sensor surfaces such as those based on metallic nanostructures, 
compatible with the working principle of the device. The present of the nanoplasmonic 
structures boosts the sensitivity and improves the feasibility of the POC device for 
biosensing applications, as recently demonstrated with gold nanohole arrays (Au-NHA) 
[18]. The generation of microarray-based spotted surface and custom-designed 
biofunctionalization over the surface of the Au-NHA sensor chips can be done with 
conventional molecular printers such as a dip-pen nanolithography instrument (Figure 
1b) which ensures the appropriate spot size and high spatial accuracy in well-defined 
patterns. The variation of OPD (ΔOPD) upon binding can therefore be correlated with 
the analyte concentration (Figure 1c). In this format, each spot can eventually be 
related to a specific biomarker, allowing the immobilization of multiple bioreceptors to 
target different sepsis biomarkers. 
CRP and IL6 immunodetection assay  
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To evaluate CRP and IL6 with the POC biosensor, we designed a direct and label-free 
immunoassay strategy, using antibodies as specific bioreceptors immobilized on the 
sensor chip surface. Direct assays are always the desired option, as they involve a 
simple one-step format, which reduces time and hands-on involvement, and facilitates 
further automation for POC deployment. In order to maximize the efficiency of the 
assay, the antibody should be as exposed as possible to facilitate the target 
recognition. Hence, a biofunctionalization based on the use of Protein G as antibody-
orienting molecule was attempted. The crystallizable fraction (Fc) of the antibodies 
interacts with Protein G forming a strong but reversible binding, thus leaving the Fab 
part, which contains the recognition binding sites, facing outwards. The array 
distribution was achieved by directly spotting Protein G solution (500 µg mL-1) onto 
clean bare sensor chips (Figure 2a). The protein anchors to the gold surface via 
physisorption. Lower concentrations of Protein G were tested leading to less amount of 
antibody adsorbed (i.e. low ΔOPD which introduced higher variability among spots). In 
order to minimize further adsorptions onto the remaining gold areas in subsequent 
steps, a blocking step was introduced. Skim milk, antifouling PEGylated compounds 
(i.e. PLL-PEG) and BSA were tested as blocking agents. However, only when using 
1% BSA blocked surfaces, a significant and reproducible attachment of the specific 
antibody (anti-CRP or anti-IL6 at 250 µg mL-1) onto the Protein G spots was observed 
(i.e. higher ∆OPD, see Figure 2c as a representative example). The other blocking 
agents probably interacted with the Protein G, preventing the subsequent binding of the 
antibody. For this reason, blocking with BSA was selected for further experiments. The 
mean of 64 spots was measured for 𝑂𝑃𝐷𝑡0and for 𝑂𝑃𝐷𝑡𝑡 as working with several 
averaged OPD values reduced variability and improved reliability of the measurements. 
Figure 2b shows the mean OPD values obtained in several sensor chips (n=30) for 
anti-CRP and anti-IL6 arrays, respectively. The same OPD pattern was observed in 
both cases with very similar overall signals and excellent reproducibility according to 
the SD obtained. Protein G was physically adsorbed on the Au-NHA chip, resulting in 
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mean OPD values around 22. After the BSA blocking, the OPD is reduced between 3-4 
units, which suggests that a layer of BSA was created over the gold surface attaching 
to the free remaining gold areas of the sensor chip. The addition of a monolayer of BSA 
changes the surface reference (i.e. it increases the OPD as a result of the adsorption), 
thus, reducing the ΔOPD between the protein G spots and the surrounding area. As 
can be seen, the intensity increases considerably after incubation with the antibody 
(OPD values of 35.7 ± 5.4 and 40.00 ± 5.1 for anti-CRP and anti-IL6 respectively), 
which confirms the preferential avidity of antibody for the immobilized Protein G. It is 
worth noting that other ways of anchoring antibodies were tested, such as covering the 
whole surface with a Protein G layer (through its covalent attachment to a self-
assembled monolayer) followed by antibody spotting or by also spotting biotinylated 
antibodies over a streptavidin coated layer. However, the antibody coated sensor chips 
showed less reproducibility and overall lower OPD signals (i.e. less number of 
receptors on the surface) which resulted in biofunctionalized sensor chips with worst 
performance (data not shown).  
The specificity provided by the chosen strategy was assessed with different controls as 
summarized in the Figure 3 for the CRP assay. We observed that the addition of the 
target protein resulted in a clear signal enhancement ((ΔOPD= 8.83, in Figure 3(1)). 
However, no OPD increase was observed if the array was incubated with a different 
protein (in Figure 3(2)). Similarly, incubation of CRP over a non-specific antibody 
resulted in negligible increase in the OPD (ΔOPD= -1.47) (see Figure 3(3)). Moreover, 
in the absence of any antibody (i.e. only spotted Protein G arrays and BSA) the CRP 
did not bind (Figure 3(4) corroborating the lack of non-specific binding over the blocked 
surface. These different tests confirmed that the signal corresponds exclusively to the 
specific recognition of the protein for its specific antibody (in this case, CRP and anti-
CRP, but extendable to any other antigen-antibody pair). 
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With the aforementioned conditions the corresponding calibration curves for both CRP 
and IL6 were obtained by incubating several arrays (8x8 spots) with different target 
concentrations (Figure 4a and c). The calibration curve for CRP showed a linear 
concentration-dependent region before reaching a saturation. A limit of detection (LoD) 
of 18 μg mL-1 was estimated. Since CRP levels in blood plasma of healthy individuals 
are commonly found below 10 µg mL-1 and can drastically increase to around 300 µg 
mL-1 in patients with severe infection [19], our approach can comfortably allow the 
detection of this protein in any infection particularly, sepsis. In the case of IL6, a linear 
response was observed without reaching saturation for the range of concentrations 
analyzed. Although it showed a good fitting (R2 =0.9647) the LoD was relatively high 
(LoD= 88 µg mL-1) for the requirements for sepsis diagnosis. The affinity of the 
antibody might have an influence in this lower level of detectability compared for 
instance with CRP. However, this can be also associated to the much lower MW of IL6, 
since the working principle of the device is related to the refractive index changes on 
the surface, which in turn is related to the mass (as described in the experimental 
section and ref [17]).  
In order to establish the accuracy of the method, some spiked blank samples for both 
biomarkers that fit within the linear range of the curve were prepared and analyzed with 
the biosensor. Figure 4b and d shows the correlation of concentrations with spiked 
samples. The slopes of the corresponding linear fittings are 0.817 for CRP and 0.996 
for IL6, respectively. According to this, IL6 assay, with a slope almost equal to 1, shows 
an excellent accuracy. In the case of CRP there is a slight underestimation probably 
due to the high concentration range close to the saturation area (i.e. above 200 µg mL-
1). Narrowing down the quantification to the lower concentration range (up to 100 µg 
mL-1) can ensure a higher level of accuracy. 
CRP and IL6 multiplexed detection  
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Based on these results, the simultaneous detection of both CRP and IL6 in the same 
sensor chip was attempted to demonstrate the feasibility of performing multiplexed 
analysis with the POC device. Gold NHA sensor chips were prepared as depicted in 
the Figure 5a. Four 8x8 microarrays were spatially distributed to facilitate further 
incubation with both the antibodies in the biofunctionalization step and the biomarkers 
for the detection. Two microarrays were functionalized with anti-CRP and the other two 
with anti-IL6. Finally, both targets were incubated either individually or together in one 
solution. Two different target concentrations were evaluated (100 and 200 µg mL-1). 
The results are summarized in Figure 5a. When tested individually, only in the 
microarrays where the protein was incubated with its specific antibody, an increase in 
the OPD was observed, which confirms the specificity of both assays. When analyzed 
together as a single solution containing both CRP and IL-6 at the same concentration 
(200 µg mL-1) we observed similar ∆OPDs (see Figure 5b), although slightly higher for 
CRP compared with the same concentration in a solution only containing this protein. A 
possible reason for this behavior could be related to the high concentration of CRP 
used in this experiment (i.e. 200 µg mL-1 of CRP in 10 µL) which, according to our 
experience, resulted in the formation of the so-called “coffee ring effect” on the spots, 
affecting the data processing to analyze the OPD. These proof-of-concept experiments 
though with a limited degree of multiplexing, exemplifies the potential of the 
biofunctionalization strategy and the POC biosensor for the simultaneous analysis of at 
least four different proteins in a single chip (i.e. in a 4-array design like the one shown 
in Figure 5). 
miRNA detection assay 
In the case of miRNA assays, a complementary DNA probe to the target sequence was 
designed to specifically detect miRNA-16 via DNA/RNA hybridization. A thiol group was 
added to the 5‘-end of the probe to facilitate the attachment to the gold surface through 
the formation of stable self-assembled monolayers (SAM) [20]. A poly thymine 
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sequence with 15 thymines (T15) was introduced after the thiol group to move away the 
complementary part from the gold surface (see Table 1). The biofunctionalization 
process (Figure 6a) involved the spotting of the thiolated DNA probes to generate the 
array followed by a blocking step of the remaining gold area with BSA. In this case, 
given the relatively small size of the miRNA (MW= 6.6 kDa) an amplification step was 
considered by using an antibody that specifically binds only to DNA/RNA duplexes [21]. 
This anti-DNA/RNA antibody does not cross-react with double stranded DNA, double 
stranded RNA, or single DNA and RNA. The considerably high molecular weight of the 
antibodies (MW= 115 kDa) triggers a larger phase change, which in turn enhances the 
overall signal and improves the overall sensitivity (Figure 6b, c).  
The immobilization steps showed similar behavior regardless of the DNA probe 
immobilized as can be seen in Figure 6d where similar signals were obtained for three 
different sequences (i.e. between 20-25 bases). The great affinity between the gold 
and thiol permits a simple, fast, direct one-step immobilization. As in the protein-based 
assay, the BSA blocking step also resulted in an OPD decrease consistent with its 
adsorption over gold (see Figure 6d). As can be seen in Figure 6c, the direct detection 
of miRNA was hardly observed, while after the addition of the specific anti-DNA/RNA 
the OPD enhancement was easily detectable. The specificity provided by the capture 
probe and the selectivity of the immobilization and blocking strategy were assessed 
with two negative control experiments. Either a non-complementary miRNA (miRNA-
21) or simply buffer without miRNA were incubated in the hybridization step, followed 
by the addition of the anti-DNA/RNA. As shown in the Figure 7a (1) a significantly 
higher enhancement was observed for the specific target (∆OPD = 7.06 for the 
antibody amplification step). However, no significant OPD increase resulted when a 
non-complementary miRNA was present Figure 7a (2) or in the absence of any miRNA 
Figure 7a (3), concluding that no DNA/RNA hybrids are formed, and corroborating the 
absence of nonspecific binding of anti-DNA/RNA over the functionalized array. 
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With the conditions previously detailed, a calibration curve for miRNA-16 was obtained 
(Figure 7b). The curve shows the signal obtained in the amplification step with the anti-
DNA/RNA. Also, in this case, a saturation region is observed for some of the miRNA 
concentrations analyzed. The LoD obtained was around 1 µM; this value is limited for 
the clinical requirements of this family of biomarkers, which commonly are within the 
nM - fM range in serum or plasma [8]. However, the developed assay using a 
sequence of DNA as bioreceptor offers a fast, straightforward label-free methodology 
for miRNA detection and illustrates the versatility of the POC device to measure not 
only proteins but also oligonucleotides.  
In general terms, the sensitivity level could be further enhanced by additional 
amplification strategies which increased the overall mass attached to the surface. 
Thus, for the protein biomarkers, the addition of a second antibody in a sandwich-
based assay, either free or even conjugated to large entities such as nanoparticles 
could be a feasible and commonly used option. This would be also possible for the 
miRNA detection by directly coupling the ant-DNA/RNA antibody to the same kind of 
nanoparticles, which would eventually increase even more the signal.  
Conclusions 
A recently developed POC device based on lens-free microscopy and light 
interferometry has been applied to the detection of specific biomarkers of different 
nature (proteins and miRNAs) with relevance in the diagnosis of sepsis. CRP and IL6 
proteins and miRNA-16 have been selected as representative biomarkers whose 
detection in plasma can help diagnose sepsis in a fast and reproducible way. The three 
assays have been optimized and are based on direct sample detection for proteins and 
require an additional amplification step for the miRNAs. The sample analysis is fast (it 
takes around 1 min after sample incubation). The LoDs obtained for the proteins are in 
the range of µg mL-1 and for miRNA in the low µM, which may be enough for CRP in 
sepsis diagnosis but should be enhanced for smaller biomarkers such as IL6 and 
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miRNAs. Improvements in the POC device such as the use of other nanoplasmonic 
structures which improve the capabilities of current configuration, or the incorporation 
of multispectral source to accomplish other sharper modes might be possible options to 
enhance the device performance. The strategies developed are reproducible and show 
excellent specificity, which make them highly suitable for further improvement and 
implementation in multiplexing configurations. The demonstration shown here with two 
protein biomarkers highlights the versatility of the technology. Current 
biofuntionalization strategy allows four different antibodies to be immobilized in a single 
chip (i.e. antibodies are not directly spotted but incubated over four different Protein G 
arrays distributed in the 1 cm2 chip surface). This could be expanded by making use of 
microfluidics which facilitated both the integration of more densely packed arrays and 
their subsequent antibody immobilization, enabling a larger level of throughput 
screening in a single measurement. Furthermore, the compactness and autonomy of 
the device paves the way towards its penetration in different decentralized 
environments, such as the hospital benchtop, at the physician desk or even at ICU unit 
for sepsis diagnosis or for other diseases. 
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Figure 1: Scheme showing the sequential steps followed for the immobilization process and 
detection with the POC device. a) Optical principle of the device. Φ= Phase difference ([17], 
adapted). b) Biofunctionalization of the Au-NHA chips using a dip-pen nanolithography 
molecular printer. A microarray image with different drops with a diameter of 55 µm and a SEM 
image of the nanoplasmonic chip are shown. c) Images of the arrays generated after software 
processing. Differences in the OPD (∆𝑂𝑃𝐷 = 𝑂𝑃𝐷𝑡𝑡 − 𝑂𝑃𝐷𝑡0 ) in each spot with and without 
the target can be related with the analyte concentration. 
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Figure 2: Protein detection immunoassay a) Scheme of the immobilization involving Protein G 
physisorption, antibody binding, blocking of gold areas and detection of CRP or IL6. b) 
Averaged OPD values obtained in each step for 30 chips for both target proteins. c) 
Representative intensity OPD maps of microarrays obtained in three different chips, showing 
the three steps of the antibodies biofunctionalization protocol.  
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Figure 3: Specificity study for the CRP assay showing the variation in the OPD in 4 different 
arrays: (1) Positive control ([CRP]= 500 μg mL-1) incubated on an anti-CRP functionalized array; 
(2) Control protein (200 μg mL-1) incubated on an anti-CRP functionalized array; (3) CRP (500 
µg mL-1) incubated on array functionalized with a non-specific antibody; (4) CRP (500 µg mL-1) 
incubated on unmodified array (i.e. only Protein G spots on a BSA blocked surface). 
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Figure 4: Calibration curves in PBS for (a) CRP and (c) IL6 obtained with the POC device. 
Correlation graphs for blind (b) CRP and (d) IL6 spiked PBS samples. All data show mean 
ΔOPD ± SD of triplicate measurements. 
  
Page 24 of 26 
 
 
Figure 5: Multiplexed measurements of CRP and IL6 with the POC device. a) Incubation of 
arrays with solutions containing only one biomarker (CRP or IL6) at 100 µg mL-1 and 200 µg 
mL-1.  
b) Incubation of arrays with a solution containing both CRP and IL6 biomarkers at a 
concentration of 200 µg mL-1. 
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Figure 6: miRNA detection assay. a) Scheme of immobilization and detection of miRNA via 
hybridization assay with SH-DNA capture probes and antibody amplification. b) Intensity OPD 
maps of three microarrays in every step of the immobilization and detection protocol for miRNA 
(miRNA-16 10 µM). c) Mean OPD ± SD corresponding to images in figure 6b. d) Averaged OPD 
obtained for the immobilization of three different DNA capture probes (specific for miRNA-16, for 
miRNA-15a and for miRNA-21) in 20 chips.  
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Figure 7: a) Specificity study for miRNA-16 assay showing the variation in the OPD in 3 
different conditions: (1) specific assay with target miRNA-16 (10 µM) followed by anti-DNA/RNA; 
(2) addition of non-complementary miRNA (miRNA-21 = 10 µM) followed by anti-DNA/RNA; (3) 
no addition of any miRNA (i.e. only buffer) followed by anti-DNA/RNA. All data show mean OPD 
± SD of triplicate measurements. b) Calibration curve for miRNA-16 in PBS. The signals 
correspond to the amplification step performed with [anti-DNA/RNA] = 80 µg mL-1. All data show 
mean ΔOPD ± SD of triplicate measurements. 
 
